Back
 PP  Vol.5 No.1 , January 2014
Effects of the Novel Anti-Asthenic Drug Ladasten on Behavior and T-Cell Subsets Alterations in a Social Defeat Animal Model of Depression
Abstract: The aim of the present study was to investigate the effects of the anti-asthenic drug ladasten on behavioral patterns and T-cell subsets in blood, spleen, and thymus in socially stressed male C57Bl/6 mice. Mice subjected to social defeat stress (SDS) for 25 days developed a depressive-like phenotype. The submissive SDS animals were assigned to one of two treatment groups: one group was treated with ladasten (30 mg/kg, i.p.) for up to 5 days, and the other one was administered vehicle as a control. Twenty four hours after the last injection, behavioral parameters were tested, and trunk blood and tissue samples were collected. SDS mice from the vehicle-treated group showed a subordinate and passive avoidance behavior with significantly decreased spontaneous locomotor activity (SLA) and exhibited impaired parameters in the forced swimming test (FST). Changes in behavioral status were correlated with an increase spleen weight, a decrease in thymic index and a shift in the CD4/CD8 balance toward T-cytotoxic cells. The behavior parameters were reversed in the group treated with ladasten compared to the untreated SDS group and were similar to those of unstressed mice. Treatment of socially stressed mice with ladasten normalized the amount of T-lymphocyte cells in the blood, spleen, and thymus. These findings support the notion that depression is accompanied by cell-mediated immune activation and that targeting this pathway may be a new therapeutic approach for treatment. Furthermore, our data support further investigations of ladasten as a potent anti-depressive drug which can be used alone as well as in combination with other anti-depressants.
Cite this paper: A. Tallerova, L. Kovalenko, I. Tsorin, A. Durnev and S. Seredenin, "Effects of the Novel Anti-Asthenic Drug Ladasten on Behavior and T-Cell Subsets Alterations in a Social Defeat Animal Model of Depression," Pharmacology & Pharmacy, Vol. 5 No. 1, 2014, pp. 4-10. doi: 10.4236/pp.2014.51002.
References

[1]   R. C. Ho, L. F. Neo, A. N. Chua, A. A. Cheak and A. Mak, “Research on Psychoneuroimmunology: Does Stress Influence Immunity and Cause Coronary Artery Disease?” Annals of the Academy of Medicine, Singapore, Vol. 39, No. 3, 2010, pp. 191-196.

[2]   M. Maes, B. Leonard, A. M. Myint, M. Kubera and R. Verkerk, “The New ‘5-HT’ Hypothesis of Depression: Cell-Mediated Immune Activation Induces Indoleamine 2,3-Dioxygenase, Which Leads to Lower Plasma Tryptophan and an Increased Synthesis of Detrimental Tryptophan Catabolites (TRYCATs), Both of Which Contribute to the Onset of Depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 35, No. 3, 2011, pp. 702-721.
http://dx.doi.org/10.1016/j.pnpbp.2010.12.017

[3]   M. Kubera, E. Obuchowicz, L. Goehler, J. Brzeszcz and M. Maes, “In Animal Models, Psychosocial Stress-Induced (Neuro)Inflammation, Apoptosis and Reduced Neurogenesis Are Associated to the Onset of Depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 35, No. 3, 2011, pp. 744-759.
http://dx.doi.org/10.1016/j.pnpbp.2010.08.026

[4]   B. E. Leonard and M. Maes, “Mechanistic Explanations How Cell-Mediated Immune Activation, Inflammation and Oxidative and Nitrosative Stress Pathways and Their Sequels and Concomitants Play a Role in the Pathophysiology of Unipolar Depression,” Neuroscience and Biobehavioral Reviews, Vol. 36, No. 2, 2012, pp. 764-785.
http://dx.doi.org/10.1016/j.neubiorev.2011.12.005

[5]   A. M. Myint, B. E. Leonard, H. W. Steinbusch and Y. K. Kim, “Th1, Th2, and Th3 Cytokine Alterations in Major Depression,” Journal of Affective Disorders, Vol. 88, No. 2, 2005, pp. 167-173.
http://dx.doi.org/10.1016/j.jad.2005.07.008

[6]   B. Dean, “Understanding the Role of Inflammatory-Related Pathways in the Pathophysiology and Treatment of Psychiatric Disorders Evidence from Human Peripheral Studies and CNS Studies,” International Journal of Neuropsychopharmacology, Vol. 14, No. 7, 2011, pp. 997-1012. http://dx.doi.org/10.1017/S1461145710001410

[7]   M. Maes, B. Leonard, A. Fernandez, M. Kubera, G. Nowak, R. Veerhuis, A. Gardner, P. Ruckoanich, M. Geffard, C. Altamura, P. Galecki and M. Berk, “(Neuro)Inflammation and Neuroprogression as New Pathways and Drug Targets in Depression: From Antioxidants to Kinase Inhibitors,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 35, No. 3, 2011, pp. 659-663.
http://dx.doi.org/10.1016/j.pnpbp.2011.02.019

[8]   C. Prica, M. Hascoet and M. Bourin, “Is Co-Administration of Bupropion with SSRIs and SNRIs in Forced Swimming Test in Mice, Predictive of Efficacy in Resistant Depression?” Behavioural Brain Research, Vol. 194, No. 1, 2008, pp. 92-99.
http://dx.doi.org/10.1016/j.bbr.2008.06.028

[9]   N. G. Bogdan, N. V. Kolotilinskaya, B. A. Badyshtov, “Comparative Study of Ladasten and Afobazol Influence on Psychophysiological Parameters of Healthy Volunteers,” International Journal of Neuropsychopharmacology, Vol. 85, 2012, p. 380.

[10]   G. G. Neznamov, S. A. Siuniakov, E. S. Teleshova and D. V. Chumakov, “Ladasten, the New Drug with Psychostimulant and Anxiolytic Actions in Treatment of Neurasthenia (Results of the Comparative Clinical Study with Placebo),” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, Vol. 109, No. 5, 2009, pp. 20-26.
http://www.ncbi.nlm.nih.gov/pubmed/?term=19491814

[11]   S. B. Seredenin, M. A. Yarkova, B. A. Badyishtov, B. M. Pyaten, N. I. Avdyunina, I. S. Morozov, T. A. Voronina and G. G. Neznamov, “Anxiolytic Drug,” Patent RF 2009, № 2376986.
http://www.fips.ru/cdfi/Fips2009.dll/CurrDoc?SessionKey=ITLG5RDJ7RZSIA4ARANR&GotoDoc=2&Query=11

[12]   S. A. Siuniakov, S. A. Grishin, E. S. Teleshova, G. G. Neznamov and S. B. Seredenin, “Pilot Clinical Trial of Ladasten,” Experimental and Clinical Pharmacology, Vol. 69, No. 4, 2006, pp. 10-15.
http://www.ncbi.nlm.nih.gov/pubmed/?term=16995430

[13]   M. A. Iarkova, M. V. Voronin and S. B. Seredenin, “Studying the Mechanisms of Ladasten Action,” Experimental and Clinical Pharmacology, Vol. 68, No. 3, 2005, pp. 3-6.
http://www.ncbi.nlm.nih.gov/pubmed/16047669

[14]   M. Kh. Salimgareeva, R. S. Yamidanov, Y. V. Vakhitova and S. B. Seredenin, “Mechanism of Action of Ladasten: Activation of Gene Expression for Neurotrophins and Motogen-Activated Kinases,” Bulletin of Experimental Biology and Medicine, Vol. 152, No. 3, 2012, pp. 313-317. http://www.ncbi.nlm.nih.gov/pubmed/?term=22803074 http://dx.doi.org/10.1007/s10517-012-1516-z

[15]   L. P. Kovalenko, A. V. Tallerova, S. V. Alekseeva, A. D. Durnev and S. B. Seredenin, “The Main Proinflammatory Cytokines in Neuroimmune Interactions,” European Neuropsychopharmacology, Vol. 21, Suppl. 2, 2011, pp. S122-S123. http://dx.doi.org/10.1016/S0924-977X(11)70135-3

[16]   Iu. V. Vakhitova, S. V. Sadovnikov, R. S. Iamidanov and S. B. Seredenin, “Cytosine Demethylation in the Tyrosine Hydroxylase Gene Promoter in the Hypothalamus Cells of the Rat Brain under the Action of an Aminoadamantane Derivative Ladasten,” Genetika, Vol. 42, No. 7, 2006, pp. 968-975.
http://www.ncbi.nlm.nih.gov/pubmed/?term=16915929

[17]   A. I. Davydova, P. M. Klodt, V. S. Kudrin, E. A. Kuznetsova and V. B. Narkevich, “Neurochemical Study of Effects of the New Anxiolitic Drugs Afobazole and Ladasten on the Synthesis and Metabolism of Monoamines and Their Metabolites in Brain Structures of Wistar Rat on the Model of Monoamine Synthesis Blockade Induced by NSD-1015—Aromatic Amino Acid Decarboxylase Inhibitory,” Experimental and Clinical Pharmacology, Vol. 73, No. 3, 2010, pp. 2-6.
http://www.ncbi.nlm.nih.gov/pubmed/?term=20408420

[18]   M. Mikhaylova, J. V. Vakhitova, R. S. Yamidanov, M. Kh. Salimgareeva, S. B. Seredenin and T. Behnisch, “The Effects of Ladasten on Dopaminergic Neurotransmission and Hippocampal Synaptic Plasticity in Rats,” Neuropharmacology, Vol. 53, No. 5, 2007, pp. 601-608.
http://dx.doi.org/10.1016/j.neuropharm.2007.07.001

[19]   R. S. Yamidanov, M. Kh. Salimgareeva, S. V. Sadovnikov, Y. V. Vakhitova, V. M. Govorun and S. B. Seredenin, “Proteomic Analysis and Identification of Ladasten Target Proteins in Rat Brain,” Bulletin of Experimental Biology and Medicine, Vol. 149, No. 6, 2012, pp. 775-778. http://dx.doi.org/10.1007/s10517-010-1050-9

[20]   T. V. Grekhova, R. R. Gainetdinov, T. D. Sotnikova, L. M. Krasnykh, V. S. Kudrin, S. A. Sergeeva and I. S. Morozov, “The Effect of Bromantane, a New Immunustimulant with Psychostimulating Action, on Release and Metabolism of Dopamine in the Dorsal Striatum of Freely Moving Rats: A Microdialysis Study,” Bulletin of Experimental Biology and Medicine, Vol. 119, No. 3, 1995, pp. 302-304. http://dx.doi.org/10.1007/BF02445840

[21]   V. S. Kudrin, S. A. Sergeeva, L. M. Krasnykh, I. I. Miroshnichenko, T. V. Grekhova and R. R. Gainetdinov, “The Effects of Bromantane on Dopamineand 5-Hydroxytryptopanergic Systems of Rat Brain,” Experimental and Klinical Pharmacology, Vol. 58, No. 4, 1995, pp. 8-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=7580761

[22]   I. S. Morozov, G. S. Pukhova, N. A. Avdulov, S. A. Sergeeva, A. A. Spasov and I. N. Iezhitsa, “The Mechanisms of the Neurotropic Action of Bromantane,” Experimental and Clinical Pharmacology, Vol. 62, No. 1, 1999, pp. 11-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=10198757

[23]   H. M. Savignac, N. P. Hyland, T. G. Dinan and J. F. Cryan, “The Effects of Repeated Social Interaction Stress on Behavioral and Physiological Parameters in a Stress-Sensitive Mouse Strain,” Behavioural Brain Research, Vol. 216, No. 2, 2011, pp. 576-584.
http://dx.doi.org/10.1016/j.bbr.2010.08.049

[24]   G. Beitia, L. Garmendia, A. Azpiroz, O. Vegas, P. F. Brainb and A. Arregi, “Time-Depend Behavioral, Neurochemical, and Immunity Consequences of Repeated Experiences of Social Defeat Stress in Male Mice and the Ameliorative Affects of Fluoxetine,” Brain Behavior and Immunity, Vol. 19, No. 6, 2005, pp. 530-539.
http://dx.doi.org/10.1016/j.bbi.2004.11.002

[25]   N. M. Tsankova, W. Berton, F. Kumar, R. I. Neve and E. J. Nestler, “Sustained Hippocampal Chromatin Regulation in a Mouse Model of Depression and Antidepressant Action,” Nature Neuroscience, Vol. 9, 2006, pp. 519-525.
http://dx.doi.org/10.1038/nn1659

[26]   M. B. Wilkinson, G. Xiao, A. Kumar, Q. LaPlant, W. Renthal, D. Sikder, T. J. Kodadek and E. J. Nestler, “Imipramine Treatment and Resiliency Exhibit Similar Chromatin Regulation in the Mouse Nucleus Accumbens in Depression Models,” The Journal of Neuroscience, Vol. 29, No. 24, 2009, pp. 7820-7832.
http://dx.doi.org/10.1523/JNEUROSCI.0932-09.2009

[27]   S. A. Golden, H. E. Covington III, O. Berton and S. J. Russo, “A Standardized Protocol for Repeated Social Defeat Stress in Mice,” Nature Protocols, Vol. 6, 2011, pp. 1183-1191. http://dx.doi.org/10.1038/nprot.2011.361

[28]   N. N. Kudryavtseva, D. F. Avgustinovich, N. P. Bondar, M. V. Tenditnik and I. L. Kovalenko, “An Experimental Approach for the Study of Psychotropic Drug Effects under Simulated Clinical Conditions,” Current Drug Metabolism, Vol. 9, No. 4, 2008, pp. 352-360.
http://dx.doi.org/10.2174/138920008784220592

[29]   D. F. Avgustinovich, I. L. Kovalenko and N. N. Kudryavtseva, “A Model of Anxious Depression: Persistence of Behavioral Pathology,” Neuroscience and Behavioral Physiology, Vol. 35, No. 9, 2005, pp. 917-924.
http://dx.doi.org/10.1007/s11055-005-0146-6

[30]   O. Vegas, E. Fano, P. F. Brain, A. Alonso and A. Azpiroz, “Social Stress, Coping Strategies and Tumor Development in Male Mice: Behavioral, Neuroendocrine and Immunological Implications,” Psychoneuroendocrinology, Vol. 31, No. 1, 2006, pp. 69-79.
http://dx.doi.org/10.1016/j.psyneuen.2005.05.013

[31]   G. V. Idova, M. A. Cheido and E. N. Zhukova, “Dependence of Stress-Induced Alterations of Immune Response on Animal’s Behavior. The Role for Neuromediators,” International Journal of Psychophysiology, Vol. 69, No. 3, 2008, p. 146.
http://dx.doi.org/10.1016/j.ijpsycho.2008.05.360

[32]   M. P. Kaster, V. M. Gadotti, J. B. Calixto, A. R. S. Santos and A. L. S. Rodrigues, “Depressive-Like Behavior Induced by Tumor Necrosis Factor-α in Mice,” Neuropharmacology, Vol. 62, No. 1, 2012, pp. 419-426.
http://dx.doi.org/10.1016/j.neuropharm.2011.08.018

[33]   W. Marks, N. M. Fournier and L. E. Kalynchuk, “Repeated Exposure to Corticosterone Increase DepressionLike Behavior in Two Different Versions of the Forced Swim Test without Altering Nonspecific Locomotor Activity or Muscle Strength,” Physiology and Behavior, Vol. 98, No. 1-2, 2009, pp. 67-72.
http://dx.doi.org/10.1016/j.physbeh.2009.04.014

[34]   R. Dantzer, B. Rose-Marie, N. Castanon, K. W. Kelley, J.-P. Konsman, S. Laye, J. Lestage and P. Parnet, “Cytokines, Sickness Behavior, and Depression,” In: R. Ader, Ed., Psychoneuroimmunology, 2007, pp. 281-318.
http://dx.doi.org/10.1016/B978-012088576-3/50019-8

[35]   L. Domínguez-Gerpe, “Stress-Induced Alterations in the Programmed Natural Cycles of Post-Natal Lymphoid Organ Development in C57BL/6 Mice: Evidence for a Regulatory Feedback Relationship between Bone Marrow and Thymus,” Immunobiology, Vol. 212, No. 8, 2007, pp. 613-627. http://dx.doi.org/10.1016/j.imbio.2007.04.005

[36]   M. J. Billard, A. L. Gruver and G. D. Sempowski, “Acute Endotoxin-Induced Thymic Atrophy Is Characterized by Intrathymic Inflammatory and Wound Healing Responses,” PLos One, Vol. 6, 2011, Article ID: e17940.
http://dx.doi.org/10.1371/journal.pone.0017940

[37]   M. G. Reyes-Garsia and F. Garcia-Tamayo, “A Neurotransmitter System That Regulates Macrophage Pro-Inflammatory Functions,” Journal of Neuroimmunology, Vol. 216, No. 1, 2009, pp. 20-30.
http://dx.doi.org/10.1016/j.jneuroim.2009.06.024

 
 
Top